Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials - 14/11/16
, Thomas Luger, MD, PhD b, Alice Gottlieb, MD, PhD c, Luis Puig, MD, PhD d, Roland Kaufmann, MD e, Enkeleida Nikaï, MS Psy f, Baojin Zhu, PhD g, Emily Edson-Heredia, MPH g, Hilde Carlier, MD g, Chen-Yen Lin, PhD g, Orin Goldblum, MD g, Gil Yosipovitch, MD hAbstract |
Background |
Itch is a prevalent symptom of psoriasis that impacts quality of life.
Objective |
We sought to describe improvements in itch severity, skin pain, and bothersomeness of skin appearance caused by psoriasis among patients who received ixekizumab, etanercept, or placebo in three 12-week, phase III clinical trials (UNCOVER-1, -2, and -3).
Methods |
The itch numeric rating scale evaluated psoriasis itch severity in all 3 trials. Skin pain was assessed by skin pain visual analog scale. Bothersomeness because of redness/discoloration, thickness, and scaling/flaking was assessed with the Psoriasis Skin Appearance Bothersomeness instrument. Psoriasis skin appearance bothersomeness and skin pain were assessed at baseline and week 12; itch numeric rating scale score was assessed at baseline and weeks 1, 2, 4, 8, and 12.
Results |
Patients who received ixekizumab demonstrated statistically significant improvements (P < .001) in itch severity, reduction in skin pain, and degree of bothersomeness compared with those who received etanercept or placebo. Clinically meaningful improvements in itch severity were achieved as early as week 1.
Limitations |
Longer-term evaluations of psoriasis symptom improvement with ixekizumab treatment are needed.
Conclusion |
After treatment with ixekizumab, patients reported fast, significant, and clinically meaningful improvements in itch severity and other psoriasis-related symptoms such as skin pain and skin appearance bothersomeness.
Le texte complet de cet article est disponible en PDF.Key words : itch, itch numeric rating scale, patient-reported outcomes, psoriasis, skin appearance bothersomeness, skin pain
Abbreviations used : HRQoL, NRS, PASI, PRO, PSAB, VAS
Plan
| Funding for this study was provided by Eli Lilly and Company. |
|
| Disclosure: Ms Nikaï, Ms Edson-Heredia, Dr Carlier, Dr Lin, and Dr Goldblum are full-time employees of Eli Lilly and Company. Dr Kimball, Dr Gottlieb, Dr Puig, Dr Kaufmann, and Dr Yosipovitch have no conflicts of interest to declare. |
Vol 75 - N° 6
P. 1156-1161 - décembre 2016 Retour au numéro
Article précédent
- Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series
- Peter Theut Riis, Jurr Boer, Errol P. Prens, Ditte M.L. Saunte, Inge E. Deckers, Lennart Emtestam, Karin Sartorius, Gregor B.E. Jemec
- Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis
- Steven R. Feldman, Diamant Thaçi, Melinda Gooderham, Matthias Augustin, Claudia de la Cruz, Lotus Mallbris, Marjorie Buonanno, Svitlana Tatulych, Mandeep Kaur, Shuping Lan, Hernan Valdez, Carla Mamolo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?